Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | GNRHR | P30968 | 4/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14627855 | 0.86 | KMT2A (0.51) | KMT2AMEN1GNRHRATMALDH1A1 | |
| SCHEMBL5468977 | 0.85 | KMT2A (0.52) | KMT2AMEN1GNRHRATMALDH1A1 | |
| SCHEMBL5464311 | 0.85 | KMT2A (0.65) | KMT2AMEN1GNRHRATMAKR1C3 | |
| SCHEMBL5470980 | 0.84 | KMT2A (0.52) | KMT2AMEN1GNRHRATMALDH1A1 | |
| SCHEMBL5467352 | 0.84 | KMT2A (0.59) | KMT2AMEN1GNRHRATMALDH1A1 | |
| SCHEMBL5466815 | 0.82 | KMT2A (0.55) | KMT2AMEN1GNRHRATMALDH1A1 | |
| SCHEMBL5461096 | 0.78 | KMT2A (0.61) | KMT2AMEN1GNRHRALDH1A1AKR1C3 | |
| SCHEMBL5471890 | 0.78 | KMT2A (0.54) | KMT2AMEN1GNRHRATMALDH1A1 | |
| SCHEMBL5461670 | 0.78 | GNRHR (0.53) | KMT2AMEN1GNRHRATMALDH1A1 | |
| SCHEMBL5470547 | 0.78 | GNRHR (0.53) | KMT2AMEN1GNRHRATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | KMT2A 1132/4885MEN1 1223/4885GNRHR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.